Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction.
Sivelestat sodium hydrate (sivelestat) is a selective inhibitor of polymorphonuclear leukocyte elastase (PMN-E). We administered sivelestat to patients with septic acute lung injury (ALI) to examine its usefulness. The primary endpoints in the study were the duration of artificial ventilation and pulmonary oxygenation ability, and the secondary endpoints were mortality and the concentrations of PMN-E, SP-D, TNF-alpha and IL-8 in blood. In the sivelestat group, the duration of artificial ventilation, pulmonary oxygenation ability, and the blood PMN-E, SP-D, TNF-alpha and IL-8 concentrations decreased significantly. Administration of sivelestat was found to reduce alveolar dysfunction and improve respiratory function, and it was suggested that early administration might be useful.
Endo
Shigeatsu
S
Department of Critical Care Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan. sendo@iwate-med.ac.jp
Sato
Nobuhiro
N
Yaegashi
Yasunori
Y
Suzuki
Yasushi
Y
Kojika
Masahiro
M
Yamada
Yasuhiko
Y
Yoshida
Yuki
Y
Nakadate
Toshihide
T
Aoki
Hidehiko
H
Inoue
Yoshihiro
Y
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016209:Interleukin-8 / Q000097:blood; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors / Q000097:blood; D007962:Leukocytes / Q000187:drug effects*; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D011652:Pulmonary Circulation / Q000187:drug effects*; D037663:Pulmonary Surfactant-Associated Protein D / Q000097:blood; D012121:Respiration, Artificial / Q000706:statistics & numerical data; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D016019:Survival Analysis; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D016209:Interleukin-8; D037663:Pulmonary Surfactant-Associated Protein D; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; C069195:sivelestat; D019272:Leukocyte Elastase; D010100:Oxygen; D005998:Glycine